Ipatasertib
Product Sizes
500 mg
£ POA
HY-15186-500MG
100 mg
£ POA
HY-15186-100MG
1 g
£ POA
HY-15186-1G
10 mg
£ POA
HY-15186-10MG
2 mg
£ POA
HY-15186-2MG
50 mg
£ POA
HY-15186-50MG
200 mg
£ POA
HY-15186-200MG
5 mg
£ POA
HY-15186-5MG
25 mg
£ POA
HY-15186-25MG
10mM/1mL
£ POA
HY-15186-10MM
About this Product
- SKU:
- HY-15186
- Additional Names:
- GDC-0068; RG7440
- CAS Number:
- 1001264-89-6
- Extra Details:
- Ipatasertib (GDC-0068) is an orally active; highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5; 18; 8 nM for Akt1/2/3; respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models[1][2].
- Molecular Weight:
- 458.00
- Purity:
- 99.88
- References:
- [1]Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55(18):8110-27.|[2]Sun L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis. 2018 Sep 5;9(9):911.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Apoptosis;PI3K/Akt/mTOR;Stem Cell/Wnt
